Insight Molecular Diagnostics Inc. (IMDX) intrinsic value & 10-year financials
Insight Molecular Diagnostics Inc. (IMDX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 27.2% a year to $4.1M, with an average return on invested capital of -102.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.01
- Market cap
- $91.7M
- Revenue (FY2025)
- $4.1M
- Revenue growth (10-yr CAGR)
- 27.2%
- ROIC (10-yr avg)
- -102.4%
- Free cash flow (FY2025)
- -$25.4M
IMDX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $4.1M | -$50.2M | -$1.65 | -$25.4M | -1260.8% | 233.8% |
| FY2024 | $1.9M | -$60.7M | -$4.66 | -$21.2M | -3245.1% | -1489.9% |
| FY2023 | $1.5M | -$27.8M | -$3.75 | -$23.6M | -1672.4% | -91.8% |
| FY2022 | $958.0K | -$72.9M | -$13.25 | -$49.9M | -1878.6% | -146.5% |
| FY2021 | $7.7M | -$64.1M | — | -$38.2M | -960.4% | -244.1% |
| FY2020 | $1.2M | -$29.9M | — | -$27.2M | -2443.3% | -161.2% |
| FY2019 | — | -$22.4M | — | -$20.6M | — | -1019.4% |
| FY2018 | — | -$15.8M | — | -$11.7M | — | 547.9% |
| FY2017 | — | -$19.4M | — | -$13.5M | — | 1460.1% |
| FY2016 | — | -$11.2M | — | -$7.6M | — | -113.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Insight Molecular Diagnostics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Insight Molecular Diagnostics Inc. has historically struggled to out-earn its cost of capital, averaging just 1.2% ROIC.
Insight Molecular Diagnostics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Insight Molecular Diagnostics Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-54.81 per share.